Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics
Crinetics Pharmaceuticals, Inc. (CRNX)
Today's Latest Price: $19.33 USD
Updated Nov 21 6:55pm
Add CRNX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CRNX Stock Summary
- Crinetics Pharmaceuticals Inc's stock had its IPO on July 18, 2018, making it an older stock than merely 1.35% of US equities in our set.
- With a price/sales ratio of 266.68, Crinetics Pharmaceuticals Inc has a higher such ratio than 98.97% of stocks in our set.
- As for revenue growth, note that CRNX's revenue has grown -30.15% over the past 12 months; that beats the revenue growth of only 6.31% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Crinetics Pharmaceuticals Inc are SCYX, RETA, FIXX, QURE, and CLSD.
- Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to www.crinetics.com.
CRNX Stock Price Chart More Charts
CRNX Price/Volume Stats
| Current price | $19.33 |
| Prev. close | $19.43 |
| Day low | $18.60 |
| Day high | $19.83 |
| 50-day MA | $17.20 |
| 200-day MA | $21.56 |
| 52-week high | $36.95 |
| 52-week low | $14.33 |
| Volume | 39,700 |
| Avg. volume | 63,143 |
| Dividend yield | N/A |
| Market Cap | 468.21M |
Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.
Top Stories View All
Best & Worst Performing Stock Industries for November 21, 2019
Best & Worst Performing Small Cap Stocks for November 21, 2019
Best & Worst Performing Mid Cap Stocks for November 21, 2019
Best & Worst Performing Large Cap Stocks for November 21, 2019
Best & Worst Performing Mega Cap Stocks for November 21, 2019
View All Top Stories
Loading social stream, please wait...